Clinical evaluation of Cefpodoxime proxetil (CPDX-PR) in the treatment of oral infections

Abstract

The clinical efficacy, safety and utility, and also the optimal dose of Cefpodoxime proxetil (CPDX-PR) in the treatment of odontogenic infections such as periodontitis, pericoronitis and osteitis of jaw were evaluated in 12 institutions. CPDX-PR was applied to 228 patients for odontogenic infections and the dosage was divided into two doses. (200 mg/day and 400 mg/day) The following results were obtained.
1) The overall clinical efficacy rate determined according to the standards established by the committee was 88.8 %. The efficacy rates were 87.3%, 88.4% and 90.3 %for periodo-ntitis, pericoronitis and osteitis of jaw, respectively. The overall efficacy rate assessed by the principal investigators was 86.5%.
2) The efficacy rates of 200 mg group and 400 mg group as judged by the committee were 87.1% and 91.2%, respectively.
3) On the bacteriological effect, eradication rate judged by the committee was 90.3 %. The MIC₈₀ against 77 strains of Oral Streptococci was 0.39 μg/ ml.
4) Side effects were noted in 3 patients (1.4%) out of 221 patients and the symptoms were diarrhea, gastralgia and dizziness. These symptoms were mild. Abnormal changes in laboratory tests were found in 12 patients (7.8 %) out of 154 patients examined. Major items were elevation of transaminase and increase of eosinophil.
From the above results, CPDX-PR was considered to be useful in the treatment of odontogenic infections. As for the recommended dose, a daily dose of 200 mg proved to exert the expected effect.